156 related articles for article (PubMed ID: 8120885)
1. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs.
Yarema KJ; Wilson JM; Lippard SJ; Essigmann JM
J Mol Biol; 1994 Mar; 236(4):1034-48. PubMed ID: 8120885
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).
Yarema KJ; Lippard SJ; Essigmann JM
Nucleic Acids Res; 1995 Oct; 23(20):4066-72. PubMed ID: 7479066
[TBL] [Abstract][Full Text] [Related]
3. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
Comess KM; Burstyn JN; Essigmann JM; Lippard SJ
Biochemistry; 1992 Apr; 31(16):3975-90. PubMed ID: 1314653
[TBL] [Abstract][Full Text] [Related]
4. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II).
Bradley LJ; Yarema KJ; Lippard SJ; Essigmann JM
Biochemistry; 1993 Jan; 32(3):982-8. PubMed ID: 8422401
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of cisplatin-induced mutations in Escherichia coli.
Burnouf D; Duane M; Fuchs RP
Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3758-62. PubMed ID: 3295870
[TBL] [Abstract][Full Text] [Related]
6. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II).
Corda Y; Anin MF; Leng M; Job D
Biochemistry; 1992 Feb; 31(7):1904-8. PubMed ID: 1536834
[TBL] [Abstract][Full Text] [Related]
7. Single d(ApG)/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli.
Burnouf D; Gauthier C; Chottard JC; Fuchs RP
Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6087-91. PubMed ID: 2201020
[TBL] [Abstract][Full Text] [Related]
8. Toxicity, mutagenicity, intracellular drug concentration and DNA binding in Escherichia coli treated with cis-platinum(II) complexes.
Razaka H; Wimmer F; Wimmer S; Villani G; Johnson NP
Chem Biol Interact; 1987 Mar; 61(3):265-75. PubMed ID: 3552271
[TBL] [Abstract][Full Text] [Related]
9. The in vitro more efficiently repaired cisplatin adduct cis-Pt.GG is in vivo a more mutagenic lesion than the relative slowly repaired cis-Pt.GCG adduct.
Brandsma JA; de Ruijter M; Visse R; van Meerten D; van der Kaaden M; Moggs JG; van de Putte P
Mutat Res; 1996 Jan; 362(1):29-40. PubMed ID: 8538646
[TBL] [Abstract][Full Text] [Related]
10. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
11. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
[TBL] [Abstract][Full Text] [Related]
12. Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2(d(GpG]], built into a specific site in a viral genome.
Naser LJ; Pinto AL; Lippard SJ; Essigmann JM
Biochemistry; 1988 Jun; 27(12):4357-67. PubMed ID: 3166983
[TBL] [Abstract][Full Text] [Related]
13. [Use of Escherichia coli recF mutant strains for analyzing the genotoxicity of complex platinum compounds].
Ptitsyn LR; Riazanova LA; Ivanov VB
Genetika; 1997 Jul; 33(7):1020-4. PubMed ID: 9378282
[TBL] [Abstract][Full Text] [Related]
14. Further characterization of an E. coli strain resistant to the toxic and mutagenic action of cis-diamminedichloroplatinum(II).
Villani G; Lherisson C; Defais M; Johnson NP
Mutat Res; 1987 Jan; 183(1):21-9. PubMed ID: 3540652
[TBL] [Abstract][Full Text] [Related]
15. 1,3-butadiene: cancer, mutations, and adducts. Part II: Roles of two metabolites of 1,3-butadiene in mediating its in vivo genotoxicity.
Recio L; Saranko CJ; Steen AM
Res Rep Health Eff Inst; 2000 Mar; (92):49-87; discussion 141-9. PubMed ID: 10925839
[TBL] [Abstract][Full Text] [Related]
16. Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II).
Pinto AL; Lippard SJ
Proc Natl Acad Sci U S A; 1985 Jul; 82(14):4616-9. PubMed ID: 3895221
[TBL] [Abstract][Full Text] [Related]
17. Role of damage-specific DNA polymerases in M13 phage mutagenesis induced by a major lipid peroxidation product trans-4-hydroxy-2-nonenal.
Janowska B; Kurpios-Piec D; Prorok P; Szparecki G; Komisarski M; Kowalczyk P; Janion C; Tudek B
Mutat Res; 2012 Jan; 729(1-2):41-51. PubMed ID: 22001238
[TBL] [Abstract][Full Text] [Related]
18. Genotoxicity and mutagenicity of chromium(VI)/ascorbate-generated DNA adducts in human and bacterial cells.
Quievryn G; Peterson E; Messer J; Zhitkovich A
Biochemistry; 2003 Feb; 42(4):1062-70. PubMed ID: 12549927
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells.
Bubley GJ; Ashburner BP; Teicher BA
Mol Carcinog; 1991; 4(5):397-406. PubMed ID: 1910483
[TBL] [Abstract][Full Text] [Related]
20. Mutational and DNA binding specificity of the carcinogen 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline.
Solomon MS; Morgenthaler PM; Turesky RJ; Essigmann JM
J Biol Chem; 1996 Aug; 271(31):18368-74. PubMed ID: 8702479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
